Abstract
After an initial 3 to 6 months of anticoagulation for venous thromboembolism (VTE), clinicians and patients face an important question: “Do we stop anticoagulants or continue them indefinitely?” The decision is easy in some scenarios (eg, stop in VTE provoked by major surgery). In most scenarios, which are faced on a day-to-day basis in routine practice, it is a challenging decision because of uncertainty in estimates in the long-term risks (principally major bleeding) and benefits (reducing recurrent VTE) and the tight trade-offs between them. Once the decision is made to continue, the next question to tackle is “Which anticoagulant?” Here again, it is a difficult decision because of the uncertainty with regard to estimates of efficacy and the safety of anticoagulant options and the tight trade-offs between choices. We conclude with the approach that we take in our clinical practice.
Cite
CITATION STYLE
Rodger, M. A., & Le Gal, G. (2018, November 27). Who should get long-term anticoagulant therapy for venous thromboembolism and with what? Blood Advances. American Society of Hematology. https://doi.org/10.1182/bloodadvances.2018020230
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.